Moomoo AIのまとめ
On August 6, 2024, Dr. Gene Salkind, a practicing neurosurgeon and Chairman of the Board of Mobiquity Technologies, Inc., filed an amendment to the Schedule 13D, disclosing a significant ownership stake in the company. The filing, which is an update to a previous Schedule 13D filing, indicates that Dr. Salkind, along with his wife and a family trust, beneficially owns 8,805,239 common shares of Mobiquity Technologies, representing approximately 53.1% of the company's outstanding common shares. This ownership includes convertible notes, options, and warrants for additional shares. The filing also notes that Dr. Salkind has no current plans that would result in any major changes to the company's structure or operations as outlined in the Schedule 13D instructions. The acquisition of shares by Dr. Salkind and his associated parties was funded through personal funds over several years. Notably, the reporting person received 7,675,160 common shares upon the automatic conversion of Series H Preferred Stock after the company's stock traded above $2 per share between July 24, 2024, and August 6, 2024. This conversion also included additional shares for accrued and unpaid dividends.
On August 6, 2024, Dr. Gene Salkind, a practicing neurosurgeon and Chairman of the Board of Mobiquity Technologies, Inc., filed an amendment to the Schedule 13D, disclosing a significant ownership stake in the company. The filing, which is an update to a previous Schedule 13D filing, indicates that Dr. Salkind, along with his wife and a family trust, beneficially owns 8,805,239 common shares of Mobiquity Technologies, representing approximately 53.1% of the company's outstanding common shares. This ownership includes convertible notes, options, and warrants for additional shares. The filing also notes that Dr. Salkind has no current plans that would result in any major changes to the company's structure or operations as outlined in the Schedule 13D instructions. The acquisition of shares by Dr. Salkind and his associated parties was funded through personal funds over several years. Notably, the reporting person received 7,675,160 common shares upon the automatic conversion of Series H Preferred Stock after the company's stock traded above $2 per share between July 24, 2024, and August 6, 2024. This conversion also included additional shares for accrued and unpaid dividends.
2024年8月6日、神経外科医でありMobiquity Technologies, Inc.の取締役会議長であるDr. Gene Salkindが、企業の重要な所有権を開示するためにSchedule 13Dの修正を申請しました。この申請は以前のSchedule 13D申請の更新であり、Dr. Salkind氏とその妻、家族のtrustがMobiquity Technologiesの普通株8,805,239株を所有していることを示しており、これは同社発行の普通株の約53.1%に相当します。この所有権には、追加の株式のためのコンバーチブルノート、オプション、およびワラントが含まれています。申請書に...すべて展開
2024年8月6日、神経外科医でありMobiquity Technologies, Inc.の取締役会議長であるDr. Gene Salkindが、企業の重要な所有権を開示するためにSchedule 13Dの修正を申請しました。この申請は以前のSchedule 13D申請の更新であり、Dr. Salkind氏とその妻、家族のtrustがMobiquity Technologiesの普通株8,805,239株を所有していることを示しており、これは同社発行の普通株の約53.1%に相当します。この所有権には、追加の株式のためのコンバーチブルノート、オプション、およびワラントが含まれています。申請書には、Dr. Salkind氏が現在、Schedule 13Dの指示に記載されている会社の構造や運営に大きな変更をもたらす予定はないことも記載されています。Dr. Salkind氏とその関連当事者による株式の取得は、数年にわたる個人資金によって行われました。特筆すべきは、報告者が2024年7月24日から8月6日の間に会社の株価が株当たり2ドルを超えた後、Series H Preferred Stockの自動換金により7,675,160株の普通株を受け取ったことです。この換金には、発生した未払いの配当に対する追加の株式も含まれています。
役に立った
役に立たない
この開示の添付ファイルは以下です：
